Cell line · CVCL_0214
Papers99
20 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 99
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Scorpion toxin peptide BMK86-P1 achieves mutation-reversible inhibition of KCNA2 at the cost of reduced efficacy in heteromers and murine neurons. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiple allosteric sites allow for synergistic enhancement of GPCR signaling. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Blood-Brain Barrier-Permeable Guanylhydrazone Analogue of the ASIC3 Activator GMQ Inhibits Human Glioblastoma Stem Cell Growth In Vitro. | ChemMedChem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Adherent expansion of CHO-K1 and HEK-293 cells in a rotating polylactic-acid bioreactor: a scalable bioprocess. | MethodsX | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Implementation of the In Vitro Seizure Liability Assay (iLAseizure) in Drug Discovery and Development: Mechanism of Action Case Studies. | Pharmacol Res Perspect | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Salmonella enterica serovar typhi limits the potency of typhoid toxin and ADP-ribosylating toxin AB to establish a persistent infection. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Humanized antibody-drug conjugates for Somatostatin receptor 2 (SSTR2)-positive tumor treatment. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides. | Cancer Biol Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Erythroferrone antagonism of BMPs is governed by a composite heparin-binding motif. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Comparative analysis reveals molecular adaptation of mammalian HCA2 to microbial metabolites. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineering novel AAV capsids by broadly attenuated and subsequent muscle-specific tropism in mice and NHPs. | Mol Ther Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Natural xanthones as α-Mangostin induce vasorelaxation involving key gating residues in the S6 domain of BK channels. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic potential of small molecules that block receptor-induced Kv7/M-current suppression in neuroprotection, seizures, and pain. | Br J Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Histamine H1 Receptor-Mediated CREB Phosphorylation via Gq Protein Signaling and Arrestin Modulation. | Pharmaceuticals (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Structure-Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off-Target Effects. | ChemMedChem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Exploratory Study of the Impact of a CCL21-Derived C-Terminal Peptide on Dendritic Cell Lymph Node Homing. | J Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Monoclonal neutralizing antibodies elicited by infection with Kaposi sarcoma-associated herpesvirus reveal critical sites of vulnerability on gH/gL. | PLoS Pathog | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker. | Pharmacol Res Perspect | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0214/papers